Развитие нейтрализующих антител при применении различных концентратов факторов свертывания крови VIII в лечении гемофилии А

УДК 616.151.514-056.7

Аннотация

Резюме. Серьезным осложнением, связанным с лечением гемофилии А, является развитие ингибиторов. В последние годы был проведён ряд исследований, посвящённых данной проблеме: RODIN, INSIGHT, FranceCoag, SIPPET и NuProtect. В данном обзоре суммируются основные результаты этих исследований. Согласно результатам рандомизированного исследования SIPPET, препараты плазматического фактора свертывания крови VIII (FVIII) обладают меньшей иммуногенностью, чем препа- раты рекомбинантного FVIII, синтезированного из клеточной линии китайских хомячков, что следует учитывать при выборе стратегии лечения. Согласно результатам исследования NuProtect, опубликованным в 2019 г., концентрат рекомбинантного FVIII, полученный из клеточной линии человека, демонстрирует профиль иммуногенности, сходный с таковым у препа- ратов плазматического FVIII. У ранее нелеченых пациентов с ненулевыми мутациями при применении симоктоког альфа не наблюдалось образования ингибиторов, также как и в случае применения препаратов плазматического FVIII в иссле- довании SIPPET.

Литература:

1. Blanchette V.S., Key N.S., Ljung L.R. et al. Definitions in hemo- philia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9. DOI: 10.1111/jth.12672. 

2. Клинические рекомендации «Гемофилия» (Утв. Минздравом России). М.: Министерство здравоохранения Российской Федера- ции, 2018. Режим доступа: https://legalacts.ru/doc/klinicheskie- rekomendatsii-gemofilija-utv-minzdravom-rossii/. 
C
3. Ljung R., Auerswald G., Benson G. et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strate- gies for difficult-to-treat patients. Eur J Haematol. 2019;102(2):111– 22. DOI: 10.1111/ejh.13193. 

4. Soucie J.M., Miller C.H., Kelly F.M. et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014;20(2):230–7. DOI: 10.1111/ hae.12302. 

5. Morfini M., Haya S., Tagariello G. et al. European study on ortho- paedic status of haemophilia patients with inhibitors. Haemo- philia. 2007;13(5):606–12. DOI: 10.1111/j.1365–2516.2007.01518.x. 

6. Gouw S.C., Van Den Berg H.M., Fischer K. et al. Intensity of fac- tor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046– 55. DOI: 10.1182/blood-2012–09–457036.
7. Walsh C. E., Soucie J. M., Miller C. H. Impact of inhibitors on hemophilia a mortality in the United States. Am J Hematol. 2015;90(5):400–5. DOI: 10.1002/ajh.23957.
8. Hoots W.K., Shapiro A.D. Factor VIII and factor IX inhibitors in patients with hemophilia. Available at: https://www.uptodate. com/contents/inhibitors-in-hemophilia-mechanisms-prevalence- diagnosis-and-eradication#H1.

1. Carpenter S.L., Michael Soucie J., Sterner S. et al. Increased prev- alence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemo- philia. 2012;18(3): e260–5. DOI: 10.1111/j.1365–2516.2011.02739.x.
2. Wight J., Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–35.
3. Allain J.P., Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood. 1976;47(6):973–82.
4. van den Berg H.M. Epidemiological aspects of inhibitor develop- ment redefine the clinical importance of inhibitors. Haemophilia. 2014;20:76–9. DOI: 10.1111/hae.12404.
5. Gouw S.С. The etiology of inhibitor development in children with severe hemophilia A. Available at: https://www.semanticscholar.org/ paper/The-etiology-of-inhibitor-development-in-children-A-Gouw/6f1081449eac66964c5667957c76aca316b5f6cc2011.

1. Gouw S.C., van der Bom J.G., van den Berg H.M. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 
2007;109(11):4648–54. DOI: 10.1182/blood-2006–11–056291. 

2. Schwaab R., Brackmann H.H., Meyer C. et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb 
Haemost. 1995;74(6):1402–6. DOI: 10.1055/s-0038–1649954. 

3. Kemball-Cook G., Tuddenham E.G., Wacey A.I. The factor VIII structure and mutation resource site: HAMSTeRS version 4. 
Nucleic Acids Res. 1998;26(1):216–9. DOI: 10.1093/nar/26.1.216. 

4. Mancuso M.E., Mannucci P.M., Rocino A. et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012;10(5):781– 
90. DOI: 10.1111/j.1538–7836.2012.04691.x. 

5. Gouw S.C., van der Bom J.G., Ljung R. et al. Factor VIII products 
and inhibitor development in severe hemophilia A. N Engl J Med. 
2013;368(3):231–9. DOI: 10.1056/NEJMoa1208024. 

6. Peyvandi F., Gouw S.C., van der Bom J.G. et al. A Randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–64. DOI: 10.1056/NEJMoa1516437. 

7. Eckhardt C.L., Van Velzen A.S., Peters M. et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemo- philia a. Blood. 2013;122(11):1954–62. DOI: 10.1182/blood-2013– 
02–483263. 

8. Calvez T., Chambost H., d’Oiron R. et al. Analyses of the France- 
Coag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica. 2018;103(1):179–89. DOI: 10.3324/haematol.2017.174706. 

9. Giles A.R., Rivard G.E., Teitel J. et al. Surveillance for factor VIII inhibitor development in the Canadian hemophilia a population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19(2):139–48. DOI: 10.1016/ S0955–3886(98)00024–1. 

10. Gouw S.C., van der Bom J.G., Auerswald G. et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemo- philia A: the CANAL cohort study. Blood. 2007;109(11):4693–7. DOI: 10.1182/blood-2006–11–056317. 

11. Astermark J., Altisent C., Batorova A. et al. Non-genetic risk fac- tors and the development of inhibitors in haemophilia: a compre- hensive review and consensus report. Haemophilia. 2010;16(5):747– 66. DOI: 10.1111/j.1365–2516.2010.02231.x. 

12. Rosendaal F.R., Palla R., Garagiola I. et al. Genetic risk stratifica- tion to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017;130(15):1757–9. DOI: 10.1182/blood-2017–06–791756. 

13. Liesner R.J., Abraham A., Altisent C. et al. Simoctocog Alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect Study. Thromb Haemost. 2021 Feb 13. [Online ahead of print]. DOI: 10.1055/s-0040–1722623. 

14. Lissitchkov T., Klukowska A., Pasi J. et al. Efficacy and safety of simoctocog alfa (Nuwiq) in patients with severe hemo- philia A: a review of clinical trial data from the GENA program. Ther Adv Hematol. 2019;10:204062071985847. DOI: 10.1177/2040620719858471.
15. Gouw S.C., van der Bom J.G., Ljung R. et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231–9. DOI: 10.1056/NEJMoa1208024.
16. Calvez T., Chambost H., Claeyssens-Donadel S. et al. Recombi- nant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124:3398– 408. DOI: 10.1182/blood-2014–07–586347.
17. Collins P.W., Palmer B.P., Chalmers E.A. et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011. Blood. 2014;124:3389–97. DOI: 10.1182/blood-2014–07–580498.
18. Goudemand J., Rothschild C., Demiguel V. et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia Blood. 2006;107(1):46–51. DOI: 10.1182/blood-2005–04–1371.
19. Chalmers E.A., Brown S.A., Keeling D. et al. Early factor VIII expo- sure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13(2):149–55. DOI: 10.1111/j.1365–2516.2006.01418.x.
20. Iorio A., Halimeh S., Holzhauer S. et al. Rate of inhibitor devel- opment in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: а systematic review. J Thromb Haemost. 2010;8(6):1256–65. DOI: 10.1111/j.1538–7836.2010.03823.x.
21. Franchini M., Coppola A., Rocino A. et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost. 2013;39(7):752–66. DOI: 10.1055/s-0033–1356715.
22. Marcucci M., Mancuso M.E., Santagostino E. et al. Type and inten- sity of FVIII exposure on inhibitor development in PUPs with haemophilia A: a patient-level meta-analysis. Thromb Haemost. 2015;113(5):1–10. DOI: 10.1160/TH14–07–0621.
23. Peyvandi F., Mannucci P.M., Palla R.net al. SIPPET: methodo- logy, analysis and generalizability. Haemophilia. 2017;23(3):353– 61. DOI: 10.1111/hae.13203.
24. Stasyshyn O., Djambas Khayat C., Iosava G. et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost. 2017;15(4):636–44. DOI: 10.1111/jth.13647.
25. EHC publishes response to the publication of the SIPPET Study. EHC — European Haemophilia Consortium. Available at: https:// ehc.eu/ehc-publishes-response-to-the-publication-of-the- sippet-study/.
26. Sandberg H., Kannicht C., Stenlund P. et al. Functional charac- teristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res. 2012;130(5):808–17. DOI: 1016/j.thromres.2012.08.311.
27. Kannicht C., Ramström M., Kohla G. et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res. 2013;131(1):78–88. DOI: 10.1016/j.thromres.2012.09.011.
28. Orlova N.A., Kovnir S.V., Vorobiev I.I. et al. Blood clotting factor VIII: from evolution to therapy. Acta Naturae. 2013;5(2):19–39.